ReviewFrontiers in cell and developmental biology2026
Dual role of ferroptosis in embryonic development, cascade amplification regulatory mechanism and targeted intervention.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is an iron-dependent regulated cell death driven by lipid peroxide accumulation. This review discusses its dual role in embryonic development. Physiologically, ferroptosis regulates cell fate and tissue remodeling through the synergistic GPX4-GSH and FSP1-CoQ10 pathways. Beyond passive cell death, iron-dependent trigger waves mediate spatially restricted cell clearance and limb muscle remodeling in avian models, integrating with Bone Morphogenetic Protein, Fibroblast Growth Factor, and Hedgehog signaling to sculpt tissue architecture as an integral component of normal morphogenesis. Pathologically, environmental stress and maternal genetic abnormalities activate ferroptosis, triggering an "iron overload → Fenton reaction → lipid peroxidation → GSH depletion/GPX4 inactivation" cascade that causes embryonic malformations. However, ferroptosis can also be directly induced by GPX4 inhibition or cysteine deprivation without prior iron overload. Current evidence relies mainly on animal models, and extrapolation to humans requires caution due to interspecies differences. Intervention targets include ferroportin regulation, GPX4/FSP1 activation, and NRF2 stabilization. Iron chelators, Ferrostatin-1, and antioxidants (NAC, astaxanthin) block the cascade at multiple nodes. Clinical use during pregnancy demands careful evaluation of off-target effects on physiological tissue sculpting. Future research should develop stage-specific and tissue-specific modulators. This review highlights the double-edged sword nature of ferroptosis, summarizes its regulatory network and intervention strategies, and proposes molecular markers (MDA, 4-HNE) for perinatal screening. Prospects include CRISPR/Cas9 and mesenchymal stem cell therapy, while multi-omics and human-specific models will accelerate clinical translation for preventing birth defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.